Agitation associated with Alzheimer’s Dementia: Mechanism of Disease

Agitation associated with Alzheimer’s Dementia: Mechanism of Disease
This video reviews hypothetical pathophysiology underlying Agitation associated with Alzheimer’s Dementia (AAD). Research has shown that in patients with Alzheimer’s dementia, agitation is associated with tau pathology and neurodegeneration in the prefrontal cortex and amygdala regions of the brain. Further studies revealed that AAD is associated with hypoactivity in prefrontal brain regions, as well as hyperactivity of the amygdala, potentially creating imbalance between emotional drive and executive function. Hypothetically, the key to this disruption in balance lies in the dysfunction of underlying neurotransmitter systems among these brain regions, the monoamines, including norepinephrine, serotonin, and dopamine.1
References:
1. US.CORP.D.23.00011 AAD Unmet Needs Deck
Disclaimers
Video was created by Otsuka Pharmaceutical Development & Commercialization, Inc.
PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC - committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.